Category: Fresenius Medical Care
A Federal Circuit court refuses to re-hear the case after a lower court throws out Baxter's $23.5 million win against Fresenius, which was charged with infringement of hemodialysis patents.
Legal troubles escalate for German healthcare giant Fresenius, which now faces a class action lawsuit over its dialysis drug GranuFlo.
Hundreds of lawsuits against Fresenius (NYSE:FMS) escalated into a class action filed in California state court with patients claiming that the German healthcare company intentionally hid serious health risks associated with its dialysis drug GranuFlo.
The FDA hands German healthcare group Fresenius a warning letter over violations cited after an April inspection of a Puerto Rico facility.
The FDA took issue with certain manufacturing processes at a Fresenius (NYSE:FMS) plant in Puerto Rico, handing the German medical healthcare company its 3rd warning letter this year.
Medical device makers DaVita and Fresenius suffer Wall Street losses amid Medicare's proposal to cut about 9% from dialysis reimbursements.
Updated July 2, 2013, at 3:45 p.m. with comment from NxStage Medical.
Updated July 2, 2013, at 5 p.m. with comment from Fresenius.
Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014.
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help identify signs of a stroke.
MASSDEVICE ON CALL — The app market is now home to the Spot a Stroke F.A.S.T. app, launched by the American Stroke Assn, the American Heart Assn. and the Ad Council.
The app, inspired by Australia's Think F.A.S.T. stroke identification app, uses the acronym to simplify the steps a user can take to determine whether someone is having a stroke. The app provides information on symptoms, suggests steps the user can take to help identify a stroke and helps find nearby hospitals and connect with emergency services.
Dialysis giant Fresenius says an FDA warning letter about a plant in Ogden, Utah, isn't likely to have an effect on its sales and earnings guidance.
Fresenius (NYSE:FMS) said today that an FDA warning letter sent to its North American division isn't likely to have an impact on its sales and earnings guidance for this year.
The German dialysis giant said the U.S. watchdog agency warned it about problems with its design verification and validation procedures at a plant in Ogden, Utah.
A spate of lawsuits across the country accuse Fresenius of deliberately concealing problems with its GranuFlo and Naturalyte products, alleging that the dialysis additives caused patients to die.
A spate of lawsuits accuse Fresenius Medical (NYSE:FMS) of deliberately concealing potentially fatal problems with a pair of since-recalled products used during dialysis.